Clinical Trials Browser

Phase 1 × lorlatinib × 30 days × Clear all

NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Phase 1 Not yet recruiting

ALK Positive Non-small Cell Lung Cancer